AHCO vs AZN

AHCO's Advanced Deterministic Scorecard reveals significant financial distress signals: a Piotroski F-Score of 2/9 indicates weak operational and financial health, with negative ROE (-4.25%) and declining revenue (-1.20% YoY). The absence of an Altman Z-Score raises concern about bankruptcy risk, while the Graham Number and intrinsic value are unavailable, suggesting no reliable fundamental valuation anchor. Despite a modest 1Y return of +10.2%, the stock has underperformed over 3Y (-20.2%) and 5Y (-72.3%), reflecting deep structural issues. Analysts recommend 'buy' with a target of $12.88, but this optimism is not supported by deteriorating fundamentals or consistent earnings beats.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.